AVTR Price Prediction Next Week
Technical Analysis: AVTR's stock has shown significant weakness, currently trading at $17.30, down from recent levels around $24. The technical indicators paint a bearish picture:
- RSI-14 at 24.06 indicates oversold conditions
- MACD is negative at -1.20 with bearish crossover
- Stock trading below all major moving averages (5,10,20,60,200-day)
- Bollinger Bands show price near lower band at $13.85, suggesting potential support
News Impact: Recent negative catalysts include:
- Mixed Q4 2024 earnings with revenue miss at $1.69B vs $1.71B expected
- Multiple analyst downgrades:
- Stifel cut PT from $28 to $26
- Barclays lowered PT from $26 to $23
- Management's conservative 2025 guidance of 1-3% organic growth
Price Prediction for Next Week: Based on technical and fundamental factors, AVTR is likely to trade between $16.80-$17.90:
- Support levels: $17.18 (Fibonacci S1), $15.93 (Fibonacci S2)
- Resistance levels: $21.23 (Fibonacci R1)
- Most probable scenario: Initial support test around $17.18 with potential bounce
- Target price: $17.60 by end of next week
Recommendation: SELL
- Current technical weakness and negative sentiment suggest further downside
- Wait for price stabilization and improved technical signals before considering long positions
- Short-term traders should look for selling opportunities on any rebounds toward $18.00
AVTR Similar Chart Price Prediction
The price of AVTR is predicted to go up 15.06%, based on the high correlation periods with HKD. The similarity of these two price pattern on the periods is 99.25%.
AVTR
HKD
Up: 15.06%Similarity: 99.25%
AVTR Revenue Forecast
AVTR EPS Forecast
AVTR FAQs
What is bull’s view on AVTR?
What is bear's view on AVTR?
What is AVTR revenue forecast for next quarter？
What is AVTR eps forecast for next quarter？
AVTR Analyst's Forecast
Tejas Savant
Morgan Stanley
Buy
2025-02-10
Price Target
$27 → $25
Upside
+32.17%
Morgan Stanley lowered the firm's price target on Avantor to $25 from $27 and keeps an Overweight rating on the shares after Q4 results were in line, led by bioprocessing upside, and Avantor returned to organic growth. FY25 guidance points to 1%-3% organic growth and double-digit EPS growth excluding the Clinical Service divestiture, which the firm calls "prudent underlying assumptions" that leave room for upside if end markets recover. The selloff post-earnings "appears overdone," the analyst added.
Daniel Arias
Stifel
Strong Buy
2025-02-10
Price Target
$28 → $26
Upside
+37.46%
Luke Sergott
Barclays
Buy
2025-02-10
Price Target
$26 → $23
Upside
+21.6%
